Monashee Investment Management Reduces Stake in Structure Therapeutics
Monashee Investment Management reduced its stake in clinical-stage biotech company Structure Therapeutics by $13.24 million during the first quarter of 2026, according to an SEC filing dated May 13, 2026. The firm sold 175,000 shares valued at approximately $11.98 million based on average closing prices for the period.
Tickers: $GPCR